Public offerings often lead to short-term negative impact on a company's stock price due to the potential dilution of existing shares. However, the capital raised is crucial for Intra-Cellular's operations and future development projects. The involvement of major financial institutions as underwriters could add credibility to the offering, but the final impact depends on market conditions and investor reception.